Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd

EXTON, Pa., April 30, 2013 /PRNewswire/ -- Absorption Systems, a global leader in preclinical contract testing of drugs, biologics, and medical devices, is pleased to announce that Vatsala Naageshwaran, Associate Director of Scientific Operations, will present a talk at the Disso 2013 Conference on May 3^rd in Mumbai, India. The title of her presentation is "Permeability classification of highly variable drugs using the in vitro Caco-2 assay." The symposium, convened under the auspices of the Society for Pharmaceutical Dissolution Science (SPDS), will run May 3^rd and 4^th at the 5-star Lalit Hotel.

The scientific program for this first annual convention of SPDS is impressive, with distinguished speakers from Europe, the United States, and India. SPDS was formed in 2012 for the purpose of disseminating the science and advancements taking place in the field of dissolution as they relate to clinical applications and methods.

"It's quite an honor to be included on the program with so many pharmaceutical scientists whose work I respect tremendously," said Ms. Naageshwaran. "I'm looking forward to interacting with them, exchanging ideas, and representing Absorption Systems." Her talk will focus on classification of drugs according to the Biopharmaceutics Classification System (BCS), a pathway in which Absorption Systems is the world leader. The pharmacokinetic parameters of highly variable drugs (those for which systemic exposure varies greatly among patients) are challenging to quantify with a clinical trial. In vitro permeability testing with Absorption Systems' validated Caco-2 cell monolayer system, on the other hand, provides consistent, accurate, and unambiguous results.

Since joining Absorption Systems in 2008, Mrs. Naageshwaran's responsibilities within the company have increased steadily. One of the areas in which she focuses her passion and depth of knowledge is in working with customers all over the world to apply the BCS and BCS-based biowaivers to avoid clinical bioequivalence testing through a more ethical and definitive in vitro test system whenever possible. "Many patient populations are undertreated because bioequivalence studies for highly variable drugs can be prohibitively expensive, resulting in many medicines being unavailable," said Mrs. Naageshwaran, who added, "This is especially true for emerging countries."

Serving more than 250 different customers annually throughout the globe, and with over 110 employees based in facilities in Exton, PA, San Diego, CA, and Panama City, Panama, Absorption Systems is a global leader in contract research for the life sciences industry. With a clear vision of the future and an unwavering commitment to innovation, the company is poised for even stronger growth going forward.

About Absorption Systems

Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, in San Diego, CA, and in Panama, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit absorption.com.

Chris Bode, Ph.D.
VP Scientific & Corporate Communications
Absorption Systems
1-610-280-1451
[email protected]
www.absorption.com

SOURCE Absorption Systems